CJC-1295/Ipamorelin

CJC-1295 and Ipamorelin form a complementary dual-peptide formulation engineered to stimulate endogenous growth hormone (GH) synthesis through two distinct, non-competing receptor pathways.

• CJC-1295 (GHRH Analog): Binds selectively to GHRH receptors on anterior pituitary somatotrophs, driving sustained baseline growth hormone signaling and downstream IGF-1 generation.

• Ipamorelin (GHS-R Agonist): Acts as a highly selective ghrelin receptor agonist, inducing rapid, acute GH release without stimulating off-target stress hormones like cortisol or prolactin.

• Amplified Pulsatile Synergy: Co-activation of both pathways produces a combined GH pulse significantly greater than either compound administered individually, preserving natural physiological release patterns.

Disclaimer: This product is sold strictly for laboratory research purposes only. Not for human or veterinary consumption, clinical trials, or therapeutic use.